Pirfenidone antagonizes TGF-β1-mediated gabapentin resistance via reversal of desmoplasia and the ‘cold’ microenvironment in pancreatic cancer
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.217287 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Jin Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Tumor Microenvironment, Drug Resistance, Neoplasm, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Owing to the desmoplastic stroma constituted by cancer-associated fibroblasts (CAFs), few immune cells infiltrate the pancreatic ductal adenocarcinoma (PDAC). Gabapentin can impede the production of ketoacids by CAFs to support cancer cells. However, in our study, we discovered a dose-dependent increase in transforming growth factor β1 (TGF-β1) levels in cancer cells in response to gabapentin. This reverse increase of TGF-β1 contributes to 'Gabapentin-resistance', leading to the antitumor effects on PDAC cell lines are negatively negotiated in the presence of pancreatic stellate cells. Pirfenidone synergistically inhibited the growth and apoptosis resistance of PDAC when combined with Gabapentin. In a mouse orthotopic PDAC model, Fe3+-mediated coordination nanodrugs, which contain gabapentin, pirfenidone and the natural polyphenol (EGCG), efficiently promoted the infiltration of naïve CD8+ T cells (CD44lowCD62Lhigh) and the accumulation of inflammatory CAFs (α-SMAlowIL-6high). This led to a nearly two-fold increase in survival compared to the control. Furthermore, we identified a new subpopulation as Hmox1highiCAFs following treatment with our nanodrugs. Hmox1highiCAFs overexpressed the Cxcl10 receptor (Sdc4) and facilitated functional CD8+ T-cell infiltration through the Tnfsf9-Tnfrsf9 axis. Overall, our nanodrugs reshape the phenotype of CAFs and enhance functional CD8+ T-cell infiltration into tumors, holding the potential to be a safe and promising therapy for PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, China.
- Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, China; Department of General Surgery (Emergency Surgery), Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001…
- Institute of Immunotherapy, Fujian Medical University, Fuzhou, Fujian, 350102, China.
- Department of General Surgery (Emergency Surgery), Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, China.
- School of Biomedical Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, China.
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China. Electronic address: zdluoman1987@163.com.
Zitieren
APA
Zhang, J., Zhang, J., Lin, R., Hou, P., Zheng, L., Jiang, C., Zhang, D., Huang, H., & Teng, T. (2024). Pirfenidone antagonizes TGF-β1-mediated gabapentin resistance via reversal of desmoplasia and the ‘cold’ microenvironment in pancreatic cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217287
Vancouver
Zhang J, Zhang J, Lin R, Hou P, Zheng L, Jiang C, et al. Pirfenidone antagonizes TGF-β1-mediated gabapentin resistance via reversal of desmoplasia and the ‘cold’ microenvironment in pancreatic cancer. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217287
BibTeX
@article{Zhang2024,
author = {Zhang, Jin and Zhang, Junrong and Lin, Ronggui and Hou, Ping and Zheng, Lihong and Jiang, Chenwei and Zhang, Da and Huang, Heguang and Teng, Tianhong},
title = {Pirfenidone antagonizes TGF-β1-mediated gabapentin resistance via reversal of desmoplasia and the ‘cold’ microenvironment in pancreatic cancer},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.217287}
}
EUVIMED